Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
We get the latest guidance on how to survive the viral season.
A rise in rates of sudden unexpected infant deaths may have been linked to an off-season surge of RSV in 2021, according to a ...
Respiratory virus season is arriving, once again, and the La Plata County Public Health Department is urging residents to ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback